Robert Jan Kwakman, MD, PhD candidate
The incidence of hand-foot syndrome (HFS) was decreased following first-line treatment with S-1 compared to capecitabine in patients with metastatic colorectal cancer (mCRC), according to findings from the phase III SALTO study that were presented at the 2017 European Cancer Congress.
Kwakman JJM, Simkens LHJ, Van Rooijen JM, et al. Randomised phase 3 study of S-1 versus capecitabine, with bevacizumab optional in both arms, in the first-line treatment of metastatic colorectal cancer (mCRC), the SALTO study of the Dutch Colorectal Cancer Group. Presented at: 2017 European Cancer Congress; January 27-30, 2017; Amsterdam, The Netherlands. Abstract 2BA.
... to read the full story